Bio-Rad Laboratories Financial Statements (BIO)
|
|
|
|
Report date
|
|
|
11.02.2022 |
17.02.2023 |
16.02.2024 |
14.02.2025 |
13.02.2026 |
|
30.04.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
2 923 |
2 802 |
2 671 |
2 567 |
2 583 |
|
2 590 |
|
Operating Income, bln rub |
|
|
500.3 |
482.6 |
337.8 |
269.0 |
270.5 |
|
239.5 |
|
EBITDA, bln rub |
? |
|
5 588 |
-4 489 |
-654.8 |
-2 142 |
475.9 |
|
34.6 |
|
Net profit, bln rub |
? |
|
4 254 |
-3 628 |
-637.3 |
-1 844 |
759.9 |
|
168.8 |
|
|
OCF, bln rub |
? |
|
669.5 |
194.4 |
374.9 |
455.2 |
532.2 |
|
510.4 |
|
CAPEX, bln rub |
? |
|
133.7 |
114.2 |
156.7 |
189.0 |
157.6 |
|
153.2 |
|
FCF, bln rub |
? |
|
535.7 |
80.3 |
218.3 |
266.2 |
374.6 |
|
357.2 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
|
OPEX, bln rub |
|
|
1 138 |
1 085 |
1 089 |
1 110 |
1 078 |
|
1 104 |
|
Cost of production, bln rub |
|
|
1 284 |
1 235 |
1 244 |
1 188 |
1 240 |
|
1 247 |
|
R&D, bln rub |
|
|
260.6 |
256.9 |
247.4 |
295.9 |
256.9 |
|
260.4 |
|
Interest expenses, bln rub |
|
|
1.55 |
38.1 |
49.4 |
48.9 |
49.0 |
|
49.3 |
|
|
Assets, bln rub |
|
|
17 799 |
13 502 |
12 299 |
9 364 |
10 577 |
|
9 790 |
|
Net Assets, bln rub |
? |
|
13 685 |
9 615 |
8 741 |
6 569 |
7 454 |
|
6 851 |
|
Debt, bln rub |
|
|
223.4 |
1 388 |
1 406 |
1 375 |
1 531 |
|
1 378 |
|
Cash, bln rub |
|
|
869.9 |
1 791 |
1 607 |
1 665 |
1 543 |
|
1 565 |
|
Net debt, bln rub |
|
|
-646.5 |
-402.6 |
-201.6 |
-289.8 |
-11.7 |
|
-186.5 |
|
|
Ordinary share price, rub |
|
|
755.6 |
420.5 |
322.9 |
328.5 |
303.0 |
|
278.8 |
|
Number of ordinary shares, mln |
|
|
29.8 |
29.8 |
29.2 |
28.2 |
27.3 |
|
27.0 |
|
|
Market cap, bln rub |
|
|
22 539 |
12 524 |
9 431 |
9 269 |
8 260 |
|
7 515 |
|
EV, bln rub |
? |
|
21 893 |
12 122 |
9 230 |
8 979 |
8 249 |
|
7 328 |
|
Book value, bln rub |
|
|
13 084 |
8 877 |
8 007 |
5 865 |
6 700 |
|
6 107 |
|
|
EPS, rub |
? |
|
142.6 |
-121.8 |
-21.8 |
-65.4 |
27.9 |
|
6.26 |
|
FCF/share, rub |
|
|
18.0 |
2.70 |
7.47 |
9.44 |
13.7 |
|
13.3 |
|
BV/share, rub |
|
|
438.6 |
298.0 |
274.1 |
207.9 |
245.7 |
|
226.6 |
|
|
EBITDA margin, % |
? |
|
191.2% |
-160.2% |
-24.5% |
-83.5% |
18.4% |
|
1.34% |
|
Net margin, % |
? |
|
145.6% |
-129.5% |
-23.9% |
-71.9% |
29.4% |
|
6.52% |
|
FCF yield, % |
? |
|
2.38% |
0.64% |
2.31% |
2.87% |
4.53% |
|
4.75% |
|
ROE, % |
? |
|
31.1% |
-37.7% |
-7.29% |
-28.1% |
10.2% |
|
2.46% |
|
ROA, % |
? |
|
23.9% |
-26.9% |
-5.18% |
-19.7% |
7.18% |
|
1.72% |
|
|
P/E |
? |
|
5.30 |
-3.45 |
-14.8 |
-5.03 |
10.9 |
|
44.5 |
|
P/FCF |
|
|
42.1 |
156.0 |
43.2 |
34.8 |
22.1 |
|
21.0 |
|
P/S |
? |
|
7.71 |
4.47 |
3.53 |
3.61 |
3.20 |
|
2.90 |
|
P/BV |
? |
|
1.72 |
1.41 |
1.18 |
1.58 |
1.23 |
|
1.23 |
|
EV/EBITDA |
? |
|
3.92 |
-2.70 |
-14.1 |
-4.19 |
17.3 |
|
211.8 |
|
Debt/EBITDA |
|
|
-0.12 |
0.09 |
0.31 |
0.14 |
-0.02 |
|
-5.39 |
|
|
R&D/CAPEX, % |
|
|
194.9% |
225.0% |
157.9% |
156.6% |
163.0% |
|
170.0% |
|
|
CAPEX/Revenue, % |
|
|
4.58% |
4.07% |
5.87% |
7.36% |
6.10% |
|
5.92% |
|
| Bio-Rad Laboratories shareholders |
